Barinthus Biotherapeutics (BRNS) Total Current Liabilities (2020 - 2026)

Barinthus Biotherapeutics has reported Total Current Liabilities for 7 years, with the latest figure at $12.0 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities changed 0.21% year-over-year to $12.0 million; the trailing twelve-month figure through Mar 2026 stood at $12.0 million (changed 0.21% YoY), and the FY2025 full-year result was $10.0 million, down 36.02% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $12.0 million, up from $10.0 million in the prior quarter.
• The five-year high for Total Current Liabilities was $18.6 million in Q3 2023, with the low at $10.0 million in Q4 2025.
• Historically, Total Current Liabilities has averaged $13.3 million across 5 years, with a median of $12.6 million in 2023.
• Annual changes were most pronounced in 2022 — Total Current Liabilities surged 120.2% — and 2025, when it plunged 36.02%.
• Barinthus Biotherapeutics' Total Current Liabilities stood at $12.2 million in 2022, then grew by 2.91% to $12.6 million in 2023, then climbed by 24.28% to $15.7 million in 2024, then sank by 36.02% to $10.0 million in 2025, then gained by 19.79% to $12.0 million in 2026.
• The last three Total Current Liabilities figures came in at $12.0 million (Q1 2026), $10.0 million (Q4 2025), and $10.8 million (Q3 2025), per Business Quant data.